δ-Opioid Receptors and Inflammatory Cytokines in Hypoxia: Differential Regulation Between Glial and Neuron-Like Cells

Translational Stroke Research

Volumn 5, Issue 4, 2014, Pages 476-483

  Wang, Qinyu ^a   Chao, Dongman ^a   Chen, Tao ^a   Sandhu, Harleen ^a   Xia, Ying ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Astrocytes; Hypoxia; IL 1 ; Inflammation; PC 12 cells; TNF ; Opioid receptors

Indexed keywords

2',6'-DIMETHYLTYROSYL-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID (1H-BENZIMIDAZOL-2-YL)(CARBOXYMETHYL)METHYLAMIDE; BENZIMIDAZOLE DERIVATIVE; DELTA OPIATE RECEPTOR; OLIGOPEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

AGONISTS; ANIMAL; ASTROCYTE; CELL CULTURE; CELL HYPOXIA; CELL SURVIVAL; INFLAMMATION; METABOLISM; NERVE CELL; PC12 CELL LINE; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ASTROCYTES; BENZIMIDAZOLES; CELL HYPOXIA; CELL SURVIVAL; CELLS, CULTURED; INFLAMMATION; NEURONS; OLIGOPEPTIDES; PC12 CELLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925347689     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-014-0342-1     Document Type: Article

References (39)

1. Lenihan CR, Taylor CT. The impact of hypoxia on cell death pathways. Biochem Soc Trans. 2013;41:657–63.
2. Beitner-Johnson D, Leibold J, Millhorn DE. Hypoxia regulates the cAMP- and Ca2+/calmodulin signaling systems in PC12 sells. Biochem Biophys Res Commun. 1998;242:61–6.
3. Soroko SI, Burykh ÉA, Bekshaev SS, Rozhkov VP. Individual systemic reactions of human organism under acute hypoxia. Boĭko ERRoss Fiziol Zh Im I M Sechenova. 2012;98:1396–415.
4. Frankola KA, Greig NH, Luo W, Tweedie D. Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2011;10:391–403.
5. Cumiskey D, Curran BP, Herron CE, O’Connor JJ. A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus. Neuropharmacology. 2007;52:1616–23.
6. Mishra A, Kim HJ, Shin AH, Thayer SA. Synapse loss induced byinterleukin-1beta requires pre- and post-synaptic mechanisms. J Neuroimmune Pharmacol. 2012;7:571–8.
7. Cieślak M, Wojtczak A, Cieślak M. Relationship between the induction of inflammatory processes and infectious diseases in patients with ischemic stroke. Acta Biochim Pol. 2013;60:345–9.
8. Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. 2012;32:1677–98.
9. Page SJ. Selective TNF, inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2013;27:395–7.
10. Otter SJ, Lucas K, Springett K, Moore A, Davies K, Young A, et al. Comparison of foot pain and foot care among rheumatoid arthritis patients taking and not taking anti-TNFα therapy: an epidemiological study. Rheumatol Int. 2011;31:1515–9.
11. Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL. Treatment of refractory chronic urticaria with tumor necrosis factor-alpha inhibitors. J Am Acad Dermatol. 2011;64:1221–2.
12. Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res. 2007;4:378–85.
13. He X, Sandhu HK, Yang Y, Hua F, Belser N, Kim DH, et al. Neuroprotection against hypoxia/ischemia: δ-opioid receptor-mediated cellular/molecular events. Cell Mol Life Sci. 2013;70:2291–303.
14. Zhang JH, Gibney GT, Xia Y. Neuroprotective role of delta-opioid receptors in cortical neurons. Am J Physiol Cell Physiol. 2002;282:C1225–34.
15. Zhang J, Qian H, Zhao P, Hong SS, Xia Y. Rapid hypoxia preconditioning protects cortical neurons from glutamate toxicity through delta-opioid receptor. Stroke. 2006;37:1094–9.
16. Ma MC, Qian H, Ghassemi F, Zhao P, Xia Y. Oxygen sensitive delta-opioid receptor-regulated survival and death signals: novel insights into neuronal preconditioning and protection. J Biol Chem. 2005;280:16208–18.
17. Chao D, Xia Y. Ionic storm in hypoxic/ischemic stress: can opioid receptors subside it? Prog Neurobiol. 2010;90:439–70.
18. Husain S, Abdul Y, Potter DE. Non-analgesic effects of opioids: neuroprotection in the retina. Curr Pharm Des. 2012;18:6101–8.
19. Tang CW, Feng WM, Du HM, Bao Y, Zhu M. Delayed administration of D-Ala2-D-Leu5-enkephalin, a delta-opioid receptor agonist, improves survival in a rat model of sepsis. Tohoku J Exp Med. 2011;224:69–76.
20. Cerbai F, Lana D, Nosi D, Petkova-Kirova P, Zecchi S, Brothers HM, et al. The neuron-astrocyte-microglia triad in normal brain ageing and in a model of neuroinflammation in the rat hippocampus. PLoS One. 2012;7:e45250.
21. Benjamins JA. Direct effects of secretory products of immune cells on neurons and glia. J Neurol Sci. 2013;333:30–6.
22. Brites D. The evolving landscape of neurotoxicity by unconjugated bilirubin: role of glial cells and inflammation. Front Pharmacol. 2012;3:88.
23. Balboni G, Salvadori S, Guerrini R, Negri L, Giannini E, Jinsmaa Y, et al. Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem. 2002;45:5556–63.
24. Chao D, Bazzy-Asaad A, Balboni G, Xia Y. Delta-, but not mu-, opioid receptor stabilizes K(+) homeostasis by reducing Ca(2+) influx in the cortex during acute hypoxia. J Cell Physiol. 2007;212:60–7.
25. Fatemi A, Wilson MA, Johnston MV. Hypoxic-ischemic encephalopathy in the term infant. Clin Perinatol. 2009;36(4):835–58.
26. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45–65.
27. Taoufik E, Tseveleki V, Chu SY, Tselios T, Karin M, Lassmann H, et al. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Brain. 2011;134:2722–35.
28. Ferrarese C, Mascarucci P, Zoia C, Cavarretta R, Frigo M, Begni B, et al. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab. 1999;19:1004–9.
29. Smith C, Emsley H, Gavin C, Georgiou R, Vail A, Barberan E, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004;4:2.
30. Liu F, McCullough LD. Inflammatory responses in hypoxic ischemic encephalopathy. Acta Pharmacol Sin. 2013;34:1121–30.
31. Shrivastava K, Llovera G, Recasens M, Chertoff M, Giménez-Llort L, Gonzalez B, et al. Temporal expression of cytokines and signal transducer and activator of transcription factor 3 activation after neonatal hypoxia/ischemia in mice. Dev Neurosci. 2013;35:212–25.
32. Ezquer ME, Valdez SR, Seltzer AM. Inflammatory responses of the substantia nigra after acute hypoxia in neonatal rats. Exp Neurol. 2006;197(2):391–8.
33. Tuttolomondo A, Di Raimondo D, di Sciacca R, Pinto A, Licata G. Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des. 2008;14:3574–89.
34. Silverstein FS, Barks JD, Hagan P, Liu XH, Ivacko J, Szaflarski J. Cytokines and perinatal brain injury. Neurochem Int. 1997;30:375–83.
35. Martin RL, Lloyd HGE, Cowan AI. The early events of oxygen and glucose deprivation: setting the scene for neuronal death? Trends Neurosci. 1994;17:251–7.
36. Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal. 2010;22:977–83.
37. Ellis A, Bennett DL. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth. 2013;111:26–37.
38. Watters O, O’Connor JJ. A role for tumor necrosis factor-α in ischemia and ischemic preconditioning. J Neuroinflammation. 2011;8:87.
39. O’Connor JJ. Targeting tumour necrosis factor-α in hypoxia and synaptic signalling. Ir J Med Sci. 2013;182:157–62.